Joint pain and physical activity among breast cancer survivors on aromatase inhibitor therapy.

e11564 Background: Adjuvant endocrine treatment that includes an aromatase inhibitor (AI) is standard care for post-menopausal women with a diagnosis of hormone-receptor positive breast cancer (BC). Joint symptoms (pain, stiffness, achiness) are common side-effects of AIs, with an estimated prevalence of 33% to 74%. Joint pain is a barrier to engaging in national guidelines recommended levels of physical activity (PA) of 150 minutes/week; yet, engagement in PA is evidence-based for relieving joint symptoms among adults with arthritis. This study investigates eligibility for a PA intervention study among BC survivors who are reported to be taking an AI and are being seen in an oncology clinic. Methods: Review of 183 consecutive patients whose medical record reported being on AI therapy. Patients were queried to determine eligibility for a PA trial that required: (1) currently taking an AI, (2) experiencing joint symptoms, and (3) < 150 minutes/week of PA. Results: 8% percent (N=15) were excluded for not cu...